Treatment and prevention of
View Patent ↗Methods and devices are disclosed for treating or preventing infections in a subject due to Pseudomonas aeruginosa using coformycin analogs and inhibitors of Pseudomonas aeruginosa 5′-methylthioadenosine deaminase (MTADA).
1. A method of treating a Pseudomonas aeruginosa ( P. aeruginosa ) infection in a subject or treating a subject who is at risk for acquiring an infection due to P. aeruginosa comprising administering to the subject a compound of formula (I) in an amount effective to treat a P. aeruginosa infection in a subject or to treat a subject who is at risk for acquiring an infection due to P. aeruginosa,
wherein formula (I) is
wherein R1 is H or OH; and
wherein Q is C1-C6 alkyl, aryl or aralkyl, wherein Q is optionally substituted with one or more methyl, hydroxyl or halogen;
or a pharmaceutically acceptable salt thereof or an ester thereof.
2. The method of claim 1 , wherein Q is C1-C3 alkyl.
3. The method of claim 1 , wherein Q is methyl.
4. The method of claim 1 , wherein Q is phenyl.
5. The method of claim 1 , wherein R1 is H.
6. The method of claim 1 , wherein R1 is OH.
7. The method of claim 1 , wherein the compound is selected from the group consisting of
or a pharmaceutically acceptable salt thereof or an ester thereof.
8. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof or an ester thereof.
9. The method of claim 1 , wherein the compound is administered in an amount that is effective to inhibit Pseudomonas aeruginosa 5′-methylthioadenosine deaminase (MTADA).
10. The method of claim 1 , wherein the compound is administered in an amount that does not inhibit growth of Pseudomonas aeruginosa.
11. The method of claim 1 , wherein the compound is administered in an amount that is effective to inhibit quorum sensing in Pseudomonas aeruginosa.
12. The method of claim 1 for treating a P. aeruginosa infection in a subject.
13. The method of claim 1 for treating a subject who is at risk for acquiring an infection due to P. aeruginosa.
14. A composition for treating a Pseudomonas aeruginosa ( P. aeruginosa ) infection in a subject or for treating a subject who is at risk for acquiring an infection due to P. aeruginosa , the composition comprising a compound of formula (I) in an amount effective to treat a P. aeruginosa infection in a subject or to treat a subject who is at risk for acquiring an infection due to P. aeruginosa , and a pharmaceutically acceptable carrier,
wherein formula (I) is
wherein R1 is H or OH; and
wherein Q is C1-C6 alkyl, aryl or aralkyl, wherein Q is optionally substituted with one or more methyl, hydroxyl or halogen;
or a pharmaceutically acceptable salt thereof or an ester thereof.
15. The composition of claim 14 , wherein the compound is selected from the group consisting of
or a pharmaceutically acceptable salt thereof or an ester thereof.
16. The composition of claim 14 , wherein the compound is
or a pharmaceutically acceptable salt thereof or an ester thereof.
17. An implantable medical device, wherein at least a portion of the device is coated or impregnated with a compound of formula (I) in an amount effective to treat a P. aeruginosa infection in a subject or to treat a subject who is at risk for acquiring an infection due to P. aeruginosa,
wherein formula (I) is
wherein R1 is H or OH; and
wherein Q is C1-C6 alkyl, aryl or aralkyl, wherein Q is optionally substituted with one or more methyl, hydroxyl or halogen;
or a pharmaceutically acceptable salt thereof or an ester thereof.
18. The implantable medical device of claim 17 , wherein the device is a catheter, a venous catheter, an arterial catheter, a transcutaneous catheter, a dialysis catheter, a urinary catheter, a tracheal catheter or a tracheal tube.
19. The implantable medical device of claim 17 , wherein the device is for implantation in a blood vessel or a body cavity.